BioCentury | May 21, 2020

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...
BC Week In Review | Jul 20, 2018
Financial News

Hotspot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on July 17 with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural...
Items per page:
1 - 2 of 2